ClinicalTrials.gg
RecruitingNCT06876896IAPUpdated Mar 19, 2026

Intra-abdominal Pressure (IAP) During PFA Treatment of A-fib/ A-Flutter

An interventional study of Accuryn Foley catheter device in Intra-Abdominal Hypertension, sponsored by Wake Forest University Health Sciences. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-19.

Sponsored by Wake Forest University Health Sciences · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to investigate the intra-abdominal pressure utilizing the Accuryn monitoring system during pulsed field ablation procedures in the electrophysiology lab compared to the type of anesthetic utilized.

Read the detailed description

Intra-abdominal pressure (IAP) may play a role in patient outcomes during ablation procedures, as increased IAP could indicate potential adverse events. Such adverse events include aspiration of stomach contents, which can lead to respiratory issues post procedure and unplanned admission to the hospital post procedure. Potrero Medical has manufactured a foley based monitoring system that has been FDA cleared for the indication of measuring intra-abdominal pressure. The Accuryn monitor allows for continuous, real-time measurement of IAP and urine output, providing data that may enhance procedural safety and provide insights into any physiological responses unique to Pulsed Field Ablation (PFA). This study aims to compare PFA in terms of safety, efficacy, and IAP changes based on type of anesthesia received.

02

Conditions studied

  • Intra-Abdominal Hypertension

Keywords

  • Atrial Fibrillation
  • Atrial Flutter
  • Pulsed Field Ablation
03

In context

Intra-Abdominal Hypertension

71 studies on the registry are indexed under Intra-Abdominal Hypertension; 16 are open to participants now.

This study's planned enrollment of 50 is below the median of 60 across 32 interventional studies indexed under Intra-Abdominal Hypertension.

Browse Intra-Abdominal Hypertension studies →

Lead sponsor

Wake Forest University Health Sciences is the lead sponsor of 1,351 studies on the registry; 201 are open to participants now.

Of its 332 completed or terminated interventional studies of FDA-regulated products, 251 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients receiving pulse field ablation procedures for standard of care treatment of atrial fibrillation and/or atrial flutter.
  • Eligible for Foley catheter placement with no to Intra-abdominal pressure (IAP) monitoring.

Exclusion criteria

Exclusion Criteria:

  • Patients under the age of 18 will be excluded.
  • History of intra-abdominal surgery within the past 6 months.
  • Known to bladder catheterization or catheter ablation; history of prostate issues / Benign prostatic hyperplasia (BPH) or frequent urinary tract infections
  • Pregnant or breastfeeding individuals
  • History of (COPD) with home oxygen use
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Accuryn Foley catheter placement

    foley catheter is made to measure intra-abdominal pressure

    Device: Accuryn Foley catheter device

Interventions

  • DeviceAccuryn Foley catheter device

    Accuryn foley catheter placed on all subjects after consent who are having treatment for atrial flutter or atrial fibrillation

06

What researchers measure

Primary outcomes

  1. Intra-abdominal pressure under Pulsed Field Ablation (PFA) under general anesthesia

    intra-abdominal pressure during PFA when general anesthetic is utilized

    Time frame: hour 2

  2. Intra-abdominal pressure under Pulsed Field Ablation (PFA) under sedation

    intra-abdominal pressure during PFA when anesthesia is sedation

    Time frame: hour 2

Secondary outcomes

  1. Incidence of Hiccups

    incidence of hiccups occurring during the planned procedure

    Time frame: hour 2

  2. Amount oral secretions

    Amount of oral secretions

    Time frame: hour 2

  3. Number of post-operative intubations

    Number of incidences requiring postoperative intubation after procedure

    Time frame: hour 2

  4. Total urine output

    Total urine output

    Time frame: hour 2

  5. Number of urinary tract infections

    Number of urinary tract infections in the week postoperatively

    Time frame: day 7

  6. Number of unplanned admissions to the hospital

    Number of unplanned admissions to the hospital

    Time frame: hour 2

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2025
First posted
Mar 14, 2025
StartActual
Mar 3, 2026
Primary completionEst.
Dec 30, 2026
CompletionEst.
Dec 30, 2026
Last update
Mar 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06876896
Responsible party
Sponsor
First posted
Mar 14, 2025
Start date
Mar 3, 2026
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Mar 19, 2026

Study contacts

Karuna Rajkumar, MD
Contact
kputturr@wakehealth.edu
832-707-0858
Karuna Rajkumar, MD
principal investigator · Wake Forest University Health Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion